Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Krystal Biotech (KRYS) stock in plain English

Free brief · no signupStart here
KRYSPublished Nov 12, 2026
Krystal Biotech Inc
Healthcare · Biotechnology
Manufactures and sells topical gene therapy treatments for rare genetic skin conditions. The business also develops redosable inhaled and dermatological candidates in clinical trials.
Assets:
Vyjuvek commercial gelTopical genetic medicine delivering over one hundred million dollars in quarterly revenue
Commercial manufacturing plantsTwo specialized gene therapy production facilities operating in Pennsylvania
Proprietary vector platformEngineered herpes simplex virus vector designed for repeated topical dosing
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

82
OPS ScoreOperating finances
Latest quote
+0.15%$315.82
$9.36B
42.9×
$470.06M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 12, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was KRYS. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Krystal Biotech (KRYS) do?

Krystal Biotech Inc (KRYS) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Manufactures and sells topical gene therapy treatments for rare genetic skin conditions. The business also develops redosable inhaled and dermatological candidates in clinical trials. Uses an engineered virus platform to deliver redosable gene therapy directly to patient skin. It is worth $9.36B on the market and sold $470.06M over the last year.

Market cap
$9.36B
P/E ratio
42.9×
Annual sales
$470.06M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 12, 2026

Brands and businesses behind KRYS

  • Vyjuvek: Prescription topical gel delivering functional collagen genes to dystrophic epidermolysis bullosa wounds for commercial revenue.

KRYS’s flags, in plain English

Each flag is a number from Krystal Biotech’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.

Stupid Cash

Can pay this year's bills 7.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 1% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Fat Margins

Profit margin of 47.9%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Priced for Perfection

Priced at 42.9 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about KRYS

How big is Krystal Biotech?

Krystal Biotech’s market cap is $9.36B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $470.06M: what customers paid the company over the last year, before any costs.

What is KRYS’s P/E ratio?

KRYS’s P/E ratio is 42.9×. Investors pay about 42.9 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with KRYS?

Commercial revenue currently relies almost entirely on a single product facing reimbursement pressure in European markets. That is one risk on Krystal Biotech’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Krystal Biotech’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. KRYS’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card